Oncology

News

EQRx's low-price drugs mission ends with Revolution buy

EQRx's pledge to disrupt the pharma pricing system started with a clarion call in 2020 but ended with a whimper today with an agreement to be taken over by Revolution Medi

News

Boehringer moves liposarcoma drug into pivotal trial

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l

News

FDA rejects Citius' revived IL-2 therapy for lymphoma

The FDA has rejected Citius Pharmaceuticals' marketing application for Lymphir, an updated version of a lymphoma therapy withdrawn from sale several years ago.

News

Enhertu shows survival boost in HER2+ solid tumours

AstraZeneca and Daiichi Sankyo's chances of getting approval for Enhertu as a therapy for all HER2-positive tumours – regardless of their location in the body – have just

R&D

Oncology R&D hits new heights, but that creates problems

The number of people globally who are being treated for cancer is steadily going up each year.

News

Consortium hunts new KRAS drugs with fruit flies and AI

The launch of the first drugs to inhibit the cancer-related protein KRAS was a milestone moment in oncology, but their efficacy wanes over time and tumours can develop res

EQRx's low-price drugs mission ends with Revolution buy

Boehringer moves liposarcoma drug into pivotal trial

FDA rejects Citius' revived IL-2 therapy for lymphoma

Enhertu shows survival boost in HER2+ solid tumours

Oncology R&D hits new heights, but that creates problems

Consortium hunts new KRAS drugs with fruit flies and AI

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

How to meet your physicians where they are online

Oncology

Editor's Picks